Opthea Limited
ASX:OPT Stock Report
Opthea Balance Sheet Health
Financial Health criteria checks 2/6 Opthea has a total shareholder equity of $-75.8M and total debt of $200.5M, which brings its debt-to-equity ratio to -264.5%. Its total assets and total liabilities are $188.8M and $264.6M respectively.
Key information
-264.5%
Debt to equity ratio
Interest coverage ratio n/a Cash US$172.47m Equity -US$75.81m Total liabilities US$264.60m Total assets US$188.79m
Recent financial health updates
Show all updates Opthea Limited, Annual General Meeting, Nov 15, 2024 Opthea Limited Appoint Executives
Price target increased by 16% to AU$0.91 Sep 23
Forecast to breakeven in 2027 Sep 10
Consensus revenue estimates decrease by 30%, EPS upgraded Sep 06 Opthea Limited Announces Executive Changes
New minor risk - Profitability Sep 02
Full year 2024 earnings: EPS and revenues miss analyst expectations Aug 31
Forecast to breakeven in 2027 Aug 31
New minor risk - Profitability Aug 12
Consensus revenue estimates decrease by 10%, EPS upgraded Jul 31
Price target decreased by 10% to AU$0.79 Jul 26
Opthea Limited Announces Board Appointments Jul 17 Opthea Limited has completed a Follow-on Equity Offering in the amount of AUD 227.314307 million. Jul 15
Forecast to breakeven in 2027 Jun 30
New major risk - Shareholder dilution Jun 24
New major risk - Shareholder dilution Jun 15
Opthea Limited Completes Enrollment in Pivotal Phase 3 Clinical Program with Sozinibercept in Wet AMD May 29
Price target increased by 14% to AU$0.90 May 02
Consensus revenue estimates decrease by 96%, EPS upgraded Apr 30
New major risk - Financial position Apr 29
Consensus revenue estimates increase by 13% Apr 27
New minor risk - Profitability Apr 26
Consensus revenue estimates decrease by 14% Apr 12
Less than half of directors are independent Apr 11
Consensus EPS estimates fall by 11% Apr 05
Opthea Limited Announces Board Changes Apr 04
Consensus revenue estimates fall by 94% Mar 23
Consensus revenue estimates decrease by 14%, EPS upgraded Mar 06
Founder recently sold AU$2.2m worth of stock Mar 02
Opthea Appoints Arshad M. Khanani as Chief Medical Advisor Feb 20
Consensus revenue estimates decrease by 94% Feb 20
Opthea Limited Completes Enrollment in First Pivotal Trial with Sozinibercept Feb 15
Opthea Strengthens Team with Key Clinical and Regulatory Hires Feb 01
Opthea Limited Announces Executive Changes Oct 28 Opthea Limited, Annual General Meeting, Nov 30, 2023
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Oct 01
Consensus revenue estimates fall by 94% Sep 14
Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Sep 01
Consensus revenue estimates increase by 15%, EPS downgraded Aug 29
Price target decreased by 9.0% to AU$1.55 Aug 28 Opthea Limited Announces “Sozinibercept” as the Nonproprietary Drug Name for OPT-302 Jul 27
Opthea Limited Announces Executive Changes Jul 11
Opthea Limited Appoints Anshul Thakral as Non-Executive Director of the Board Jun 09
Consensus revenue estimates increase by 12% May 19
Consensus EPS estimates upgraded to US$0.25 loss Mar 09
Consensus EPS estimates fall by 44% Mar 01
First half 2023 earnings released: US$0.17 loss per share (vs US$0.11 loss in 1H 2022) Feb 24
Consensus revenue estimates increase by 12% Feb 15
Opthea Limited Announces Phase 2B Trial Results of OPT-302 in Combination with Lucentis for Wet Amd Published in the Journal Ophthalmology Feb 14
Consensus forecasts updated Jan 03
Independent Non-Executive Director exercised options to buy AU$173k worth of stock. Nov 30
High number of new directors Nov 16
Opthea Limited Appoints Timothy E. Morris as Chief Financial Officer Oct 25
Opthea Limited, Annual General Meeting, Nov 16, 2022 Oct 17
Consensus forecasts updated Sep 05
Full year 2022 earnings: EPS and revenues miss analyst expectations Aug 31
Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD Aug 17
Opthea Limited, Annual General Meeting, Sep 26, 2022 Aug 16
Opthea Secures up to USD 170 Million in Non-Dilutive Financing for OPT-302 in wet AMD Aug 15
Is Opthea (ASX:OPT) In A Good Position To Invest In Growth? Jul 21
High number of new directors Jun 01
Opthea Limited Announces Data for OPT-302 in Combination with Ranibizumab for Polypoidal Choroidal Vasculopathy Presented at ARVO 2022 May 08
High number of new directors May 02
Opthea Limited Announces Board Appointments Apr 21
Consensus forecasts updated Apr 14
Here's Why We're Watching Opthea's (ASX:OPT) Cash Burn Situation Mar 24
Opthea Limited Appoints Joel Naor, as Chief Medical Officer Mar 04
Opthea Limited Appoints Joel Naor, as Chief Medical Officer Mar 03
Opthea Limited Announces Data for OPT-302 in Patients with PVC Feb 15
We're Hopeful That Opthea (ASX:OPT) Will Use Its Cash Wisely Dec 09
This Is Why Opthea Limited's (ASX:OPT) CEO Compensation Looks Appropriate Oct 12
Price target decreased to AU$2.95 Sep 03
Full year 2021 earnings released: US$0.14 loss per share (vs US$0.043 loss in FY 2020) Sep 01
Here's Why We're Not Too Worried About Opthea's (ASX:OPT) Cash Burn Situation Aug 24
Opthea Limited Expands Global Phase 3 ShORe and COAST Wet AMD Trials of OPT-302 into Canada Aug 10
High number of new directors Aug 01
Opthea's OPT-302 Granted FDA Fast Track Designation for Wet Age-Related Macular Degeneration Jul 07
Price target decreased to AU$4.24 Apr 15
Opthea Limited Treats First Patient in Phase 3 Trials of OPT-302 Mar 15
Independent Non-Executive Director exercised options to buy AU$1.1m worth of stock. Mar 06
We Think Opthea (ASX:OPT) Can Afford To Drive Business Growth Mar 01
Opthea Limited Finalizes Study Designs and Start-Up Activities for Phase 3 Pivotal Clinical Trials of OPT-302 in Wet AMD Feb 24
First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.03 loss in 1H 2020) Feb 23
New 90-day low: AU$1.75 Feb 20
New 90-day low: AU$1.81 Feb 04
Financial Position Analysis
Short Term Liabilities: OPT has negative shareholder equity , which is a more serious situation than short term assets not covering short term liabilities .
Long Term Liabilities: OPT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities .
Debt to Equity History and Analysis
Debt Level: OPT has negative shareholder equity , which is a more serious situation than a high debt level.
Reducing Debt: OPT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OPT has sufficient cash runway for more than a year based on its current free cash flow .
Forecast Cash Runway: OPT has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 43.7% each year.
Discover healthy companies Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
